Bausch Health Companies Inc. (NASDAQ:BHC)

BRIEF

published on 12/02/2024 at 14:05, 1 year 1 month ago

Bausch Health Appoints New Chief Medical Officer and Head of R&D

Innovation Pharmaceuticals R&D Bausch Health Jonathan Sadeh
PRESS RELEASE

published on 12/02/2024 at 14:00, 1 year 1 month ago

Bausch Health Appoints New Chief Medical Officer and Head of R&D
Bausch Health Companies Inc. appoints Jonathan Sadeh M.D., M.Sc as Executive VP, Chief Medical Officer & Head of R&D, emphasizing commitment to innovation & excellence

Innovation Bausch Health Companies Inc. R&D Chief Medical Officer Jonathan Sadeh
BRIEF

published on 11/18/2024 at 14:05, 1 year 2 months ago

Bausch Health's CABTREO Receives Positive Reimbursement Endorsements in Canada

Bausch Health Dermatology Acne Treatment Canada Drug Approval Reimbursement Endorsement
PRESS RELEASE

published on 11/18/2024 at 14:00, 1 year 2 months ago

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
Bausch Health, Canada announces positive reimbursement recommendations for new acne treatment CABTREO, the first triple-combination topical therapy approved in Canada

Bausch Health CABTREO Canada Acne Treatment Reimbursement
BRIEF

published on 10/30/2024 at 21:10, 1 year 3 months ago

Bausch Health Reports Strong Third Quarter 2024 Results

Adjusted EBITDA Revenue Growth Financial Performance Bausch Health Quarterly Results
PRESS RELEASE

published on 10/30/2024 at 21:05, 1 year 3 months ago

Bausch Health Announces Third Quarter 2024 Results
Bausch Health Companies Inc. reports sixth consecutive quarter of revenue and Adjusted EBITDA growth. Q3 revenues reach $2.51 billion, up 12%. GAAP Net Loss at $85 million. Raised full-year 2024 guidance

Adjusted EBITDA Revenue Growth Bausch Health Full-year Guidance Q3 Financial Results
BRIEF

published on 10/27/2024 at 17:20, 1 year 3 months ago

Salix Pharmaceuticals Presents Xifaxan Analysis at ACG 2024

Salix Pharmaceuticals XIFAXAN Hepatic Encephalopathy ACG 2024 Plenvu
PRESS RELEASE

published on 10/27/2024 at 17:15, 1 year 3 months ago

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Bausch Health's additional ACG presentation to focus on Xifaxan impact on OHE rehospitalizations and Plenvu bowel preparation efficacy at ACG 2024. Posters to share findings on treatments

Bausch Health ACG Presentation Xifaxan Impact OHE Rehospitalizations Plenvu Efficacy
BRIEF

published on 10/09/2024 at 22:10, 1 year 3 months ago

Bausch Health to Release Q3 2024 Financial Results

Conference Call Financial Announcement Webcast Q3 Results Bausch Health
PRESS RELEASE

published on 10/09/2024 at 22:05, 1 year 3 months ago

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
Bausch Health Companies Inc. will release Q3 2024 financial results on October 30, 2024, followed by a conference call and webcast discussing business updates

Financial Results Conference Call Webcast Bausch Health Q3 2024

Published on 01/31/2026 at 03:15, 1 day 14 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 1 day 15 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 1 day 15 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 1 day 17 hours ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 1 day 18 hours ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 1 day 1 hour ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 5 hours ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 14 hours ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 19 hours ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 21 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 17:45, 1 day 23 hours ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 2 days 9 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 2 days 23 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 2 days 23 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 2 days 23 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News